|
Published by: Global Markets Direct
Published: Nov. 28, 2012 - 53 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Chlamydia Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Chlamydia Infections
- Chlamydia Infections Therapeutics under Development by Companies
- Chlamydia Infections Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Chlamydia Infections Therapeutics – Products under Development by Companies
- Chlamydia Infections Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Chlamydia Infections Therapeutics Development
- Emergent BioSolutions Inc.
- CEL-SCI Corporation
- Creative Antibiotics Sweden AB
- Osel Inc.
- Wittycell S.A.S.
- Genetic Immunity, LLC
- Genocea Biosciences, Inc.
- Chlamydia Infections – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Chlamydia Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- rifalazil - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- doxycycline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ChlamyDerm Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MucoCept Platform - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Chlamydia Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- INP-1750 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Human Liporale-Chlamydia Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- WTCa Adjuvant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- WTCb adjuvant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- WTCn adjuvant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Chlamydia Infections Therapeutics – Drug Profile Updates
- Chlamydia Infections – Product Development Milestones
- Featured News & Press Releases
- Oct 04, 2012: Cempra Announces Positive Top-Line Results From Solithromycin Phase II Clinical Trial In Patients With Uncomplicated Urogenital Gonorrhea
- Sep 27, 2010: TrioBiotics Pharma AG Announces Receipt Of Notice Of Allowance Of Patent For Rifalazil For Method Of Treatment And Prophylactic Use
- Aug 09, 2010: TrioBiotics Pharma AG Announces New Strategic Direction To Focus On Rifalazil Development
- Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center’s Sexually Transmitted Infections Cooperative Research Center
- Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
- Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
- Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Chlamydia Infections, H2 2012
- Products under Development for Chlamydia Infections – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Emergent BioSolutions Inc., H2 2012
- CEL-SCI Corporation, H2 2012
- Creative Antibiotics Sweden AB, H2 2012
- Osel Inc., H2 2012
- Wittycell S.A.S., H2 2012
- Genetic Immunity, LLC, H2 2012
- Genocea Biosciences, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Chlamydia Infections Therapeutics – Drug Profile Updates
- List of Figures
- Number of Products under Development for Chlamydia Infections, H2 2012
- Products under Development for Chlamydia Infections – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractChlamydia Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Chlamydia Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chlamydia Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chlamydia Infections. Chlamydia Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Chlamydia Infections.
- A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chlamydia Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
